Showing results (371-380 of 420) with videos related to
Sort By:
Pageof 42
NPJ Precision Oncology|October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncologyHenry Hiep Vo, Siqing Fu, David S Hong, et al.Journal for Immunotherapy of Cancer|February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer typesDavid R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.Journal of the Advanced Practitioner in Oncology|October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center ExperienceFedricker D Barber, Erick Campbell, Yuko Yamamura, et al.Communications Medicine|July 6, 2026
OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancerChristoph Schultheiß, Brenda Besemer, Edith Willscher, et al.ESMO Open|October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignanciesAparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.Thyroid : Official Journal of the American Thyroid Association|February 10, 2023
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAFV600E Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort StudyXiao Zhao, Jennifer Rui Wang, Ramona Dadu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1LVivek Subbiah, Fengmin Zhao, Ragini R Kudchadkar, et al.The New England Journal of Medicine|August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsDavid M Hyman, Igor Puzanov, Vivek Subbiah, et al.Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.Pageof 42